首 页   本刊简介  编委会  审稿专家  在线期刊  写作规范  广告合作  联系我们
您现在的位置:首页 => 在线期刊 => 在线期刊 2006年 => 2期 =>失代偿期肝硬化抗病毒治疗的临床价..
失代偿期肝硬化抗病毒治疗的临床价值
Clinical values of anti-virus treatment on decompensated cirrhosis patients
文章发布日期:2009年10月10日  来源:  作者:张月荣; 张月萍; 张涛   点击次数:1682次  下载次数:552次

调整字体大小:

(此处下载失败可以在在线预览处保存副本或者右键另存为)

【摘要】:研究拉米夫定治疗失代偿期肝硬化的疗效及安全性。将活动期肝硬化和静止期肝硬化患者分成对照组和治疗组。对照组给予常规综合治疗12月;治疗组除上述治疗外,给予拉米夫定100mg/日,疗程12个月。观察治疗前后肝功能、HBV DNA、HBeAg阴转和病毒变异等。拉米夫定治疗12个月后,患者肝功能明显改善,Ch ild-pugh评分缩短(P<0.05),HBV DNA下降(P<0.05),HBeAg阴转率升高(P<0.05),血清转换率及病毒变异率无统计学意义。失代偿期肝硬化应用拉米夫定治疗可改善肝功能、阻止病情进一步发展;病毒变异率低,未见严重后果发生。
【Abstract】: To evaluate the therapy efficacy and safety of lamivudine treatment for 12 months on decompensated cirrhosis patients following chronic hepatitis B.73 decompensated cirrhosis patients were divided into two groups-46 active cirrhosis and 27 inactive cirrhosis patients.Both of groups were further divided into two smaller groups-the control groups and the treated groups.The control groups were given conventional treatment while the treated were given lamivudine 100mg/day together with conventional treatment for 12 months.Then to observe the changes of the liver functions,HBV DNA level and virus mutation.After lamivudine treatment for 12 months,decompensated cirrhosis patients were significantly improved in liver functions,with decreased Child-Pugh score(<0.05) and HBV DNA level(<0.05);the rate of HBeAg negative was higher than the control group(P<0.05).The rate of the biochemical breakthrough was not higher than the control group(P>0.05).Lamivudine treatment on decompensated c
【关键字】:肝硬化; 乙肝病毒; 活动期; 静止期; 治疗学
【Key words】:cirrhosis; hepatitis B virus; active period; inactive period; therapy
【引证本文】:

地址:长春市东民主大街519号《临床肝胆病杂志》编辑部 邮编:130061 电话:0431-88782542/3542
临床肝胆病杂志 版权所有 Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号

吉公网安备 22010402000041号